Want to see LUNG full AI Analyst Report?
LUNG Stock Chart & Stats
$1.80
-$0.17(-2.57%)
At close: 4:00 PM EST
$1.80
-$0.17(-2.57%)
Day’s Range― - ―
52-Week Range$1.13 - $3.88
Previous CloseN/A
Volume95.69K
Average Volume (3M)308.20K
Market Cap
$58.71M
Enterprise Value$47.52M
Total Cash (Recent Filing)$61.57M
Total Debt (Recent Filing)$56.29M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Aug 05, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding42,237,200
10 Day Avg. Volume245,979
30 Day Avg. Volume308,202
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.66
Price to Sales (P/S)0.99
P/FCF Ratio-2.73
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue0.54
Enterprise Value/Gross Profit0.71
Enterprise Value/Ebitda-0.99
Forecast
1Y Price Target
$3.50Price Target Upside94.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.14
Revenue Forecast (FY)$90.87M
Bulls Say, Bears Say
Bulls Say
High & Stable Gross MarginsPulmonx sustains very high gross margins (mid‑70s, 78% in Q1), typical of device/implant economics. Durable gross margin provides structural profitability leverage as revenue scales, cushions operating spend, and supports long‑term free cash flow potential if commercial traction returns.
Extended Liquidity RunwayThe five‑year facility plus ~$62M cash materially extends runway and reduces immediate refinancing risk, giving management time to execute commercialization and clinical milestones. This structural liquidity supports investment in sales hires and pivotal trials without immediate dilution.
Clinical Pipeline Could Expand TAMAdvancing the CONVERT II pivotal and potential AeriSeal approval represents a structural growth catalyst: a successful program would broaden eligible patient population and product offerings, increasing long‑term addressable market and diversifying revenue beyond core Zephyr valve implants.
Bears Say
Negative Operating Cash FlowPersistent negative operating and free cash flow means the business consumes capital to run. Long‑term funding reliance increases dilution or leverage risk, constrains reinvestment capacity, and magnifies the impact of any revenue shortfalls on solvency and strategic flexibility.
High & Rising LeverageDebt exceeding equity and a materially leveraged balance sheet reduce financial flexibility and elevate downside risk. Secured credit terms and warrants increase fixed obligations and potential dilution, making the company more sensitive to operational misses or slower revenue recoveries.
Revenue Decline & Execution RiskYear‑over‑year revenue decline and dependence on a multi‑month salesforce ramp and regulatory timing (China renewal) make growth contingent on execution. Delays in rep productivity or regulatory setbacks could prolong negative cash flow and undermine longer‑term commercial scaling plans.
Pulmonx News
LUNG FAQ
What was Pulmonx’s price range in the past 12 months?
Pulmonx lowest stock price was $1.13 and its highest was $3.88 in the past 12 months.
What is Pulmonx’s market cap?
Pulmonx’s market cap is $58.71M.
When is Pulmonx’s upcoming earnings report date?
Pulmonx’s upcoming earnings report date is Aug 05, 2026 which is in 30 days.
How were Pulmonx’s earnings last quarter?
Pulmonx released its earnings results on Apr 29, 2026. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.327 by -$0.003.
Is Pulmonx overvalued?
According to Wall Street analysts Pulmonx’s price is currently Undervalued.
Does Pulmonx pay dividends?
Pulmonx does not currently pay dividends.
What is Pulmonx’s EPS estimate?
Pulmonx’s EPS estimate is -0.28.
How many shares outstanding does Pulmonx have?
Pulmonx has 42,237,200 shares outstanding.
What happened to Pulmonx’s price movement after its last earnings report?
Pulmonx reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.327. Following the earnings report the stock price went up 6.667%.
Which hedge fund is a major shareholder of Pulmonx?
Currently, no hedge funds are holding shares in LUNG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulmonx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.50 (94.44% Upside)
$3.50 (94.44% Upside)
Hedge Fund Trend
Decreased
By 2.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $144.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 12.0%
Last 30 Days ▼ 12.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.30%
12-Months-Change
Fundamentals
Return on Equity
-92.94%
Trailing 12-Months
Asset Growth
-20.41%
Trailing 12-Months
Company Description
Pulmonx
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
LUNG Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call mixes clear near-term challenges (Q1 revenue declines, China registration-driven international disruption, ongoing net losses) with several meaningful positive developments: improved gross margin, cost reductions lowering operating expense trajectory, strengthened liquidity via a $60M credit facility, addition of U.S. treating centers and filled sales roles, and progressing pivotal clinical enrollment that could expand TAM by ~20%. Management reiterated full-year guidance of $90M–$92M and expects sequential improvement with a return to growth in H2 2026. The narrative is execution- and timing-dependent but supported by concrete operational and financial actions that materially reduce downside risk.View all LUNG earnings summariesLUNG Stock 12 Month Forecast
Average Price Target
$3.50
▲(94.44% Upside)
Technical Analysis
Apyx Medical
―
Xtant Medical Holdings
―
Sensus Healthcare
―
TELA Bio
―
Icecure Medical
―
Ownership Overview
14.06% Insiders
16.95% Mutual Funds
31.62% Other Institutional Investors
32.59% Public Companies and
Individual Investors